Gelonghui, February 4, 丨 Rendu Biology (688193.SH) announced that the company's new product hepatitis C virus nucleic acid test kit (RNA capture probe method) has obtained a product registration certificate, registration category III.
The above products can quantitatively detect hepatitis C virus (HCV) RNA in human serum samples and are used to evaluate the response and treatment effects of antiviral treatment. They are new products in the company's blood-borne infectious disease series; previously, quantitative testing products for hepatitis B RNA and AIDS in this series of products have also been certified on the market.
The acquisition of the above medical device registration certificate has further enriched the company's product categories, helped enhance the overall competitiveness of the company's in vitro diagnostic reagent business, and will have a positive impact on the company's market expansion and future operations.